Clinical characteristics of ESCC patients who underwent ESD with adjuvant radiotherapy group (RT Group).

Clinical characteristics of ESCC patients who underwent ESD with adjuvant radiotherapy group (RT Group).</p

Flow chart of study population.

Background and aimThe clinical outcome of endoscopy submucosal dissection with subsequent radiotherapy for esophageal squamous cell carcinoma remain unclear. In this study we aim to investigate the efficacy and safety of endoscopic submucosal dissection with adjuvant radiotherapy in the treatment of superficial esophageal squamous cell carcinoma involving the muscularis mucosae (T1a-MM) or the submucosa MethodsWe analyzed 20 patients with pathologically confirmed T1a-MM or T1b-SM1 esophageal squamous cell carcinoma treated by endoscopic submucosal dissection from 2016 to 2020 in Lihuili Hospital, 9 patients received adjuvant radiotherapy (RT group) and 11 patients received did not (non-RT group).ResultsAll 20 patients underwent en bloc resection, and both the vertical and horizontal margins were negative. There was no recurrence or lymph node metastasis in the RT group, and no serious complications or death were observed. In the non-RT group, 2 patients had local recurrence and 1 had distant metastasis. None of the 20 patients died of esophageal carcinoma.ConclusionsAdjuvant radiotherapy following endoscopic submucosal dissection may be a safe and effective method for the treatment of T1a-MM/T1b-SM1 superficial esophageal squamous cell carcinoma.</div

Clinical characteristics of ESCC patients who underwent ESD only group (Non-RT Group).

Clinical characteristics of ESCC patients who underwent ESD only group (Non-RT Group).</p

Survival curve.

Background and aimThe clinical outcome of endoscopy submucosal dissection with subsequent radiotherapy for esophageal squamous cell carcinoma remain unclear. In this study we aim to investigate the efficacy and safety of endoscopic submucosal dissection with adjuvant radiotherapy in the treatment of superficial esophageal squamous cell carcinoma involving the muscularis mucosae (T1a-MM) or the submucosa MethodsWe analyzed 20 patients with pathologically confirmed T1a-MM or T1b-SM1 esophageal squamous cell carcinoma treated by endoscopic submucosal dissection from 2016 to 2020 in Lihuili Hospital, 9 patients received adjuvant radiotherapy (RT group) and 11 patients received did not (non-RT group).ResultsAll 20 patients underwent en bloc resection, and both the vertical and horizontal margins were negative. There was no recurrence or lymph node metastasis in the RT group, and no serious complications or death were observed. In the non-RT group, 2 patients had local recurrence and 1 had distant metastasis. None of the 20 patients died of esophageal carcinoma.ConclusionsAdjuvant radiotherapy following endoscopic submucosal dissection may be a safe and effective method for the treatment of T1a-MM/T1b-SM1 superficial esophageal squamous cell carcinoma.</div

Summary of progression free survival.

Background and aimThe clinical outcome of endoscopy submucosal dissection with subsequent radiotherapy for esophageal squamous cell carcinoma remain unclear. In this study we aim to investigate the efficacy and safety of endoscopic submucosal dissection with adjuvant radiotherapy in the treatment of superficial esophageal squamous cell carcinoma involving the muscularis mucosae (T1a-MM) or the submucosa MethodsWe analyzed 20 patients with pathologically confirmed T1a-MM or T1b-SM1 esophageal squamous cell carcinoma treated by endoscopic submucosal dissection from 2016 to 2020 in Lihuili Hospital, 9 patients received adjuvant radiotherapy (RT group) and 11 patients received did not (non-RT group).ResultsAll 20 patients underwent en bloc resection, and both the vertical and horizontal margins were negative. There was no recurrence or lymph node metastasis in the RT group, and no serious complications or death were observed. In the non-RT group, 2 patients had local recurrence and 1 had distant metastasis. None of the 20 patients died of esophageal carcinoma.ConclusionsAdjuvant radiotherapy following endoscopic submucosal dissection may be a safe and effective method for the treatment of T1a-MM/T1b-SM1 superficial esophageal squamous cell carcinoma.</div

Clinicopathological characteristics of ESCC patients after ESD with or without radiotherapy.

Clinicopathological characteristics of ESCC patients after ESD with or without radiotherapy.</p

sj-pdf-2-jva-10.1177_11297298231225679 – Supplemental material for A comparative study on the transbrachial and transfemoral approaches for the treatment of superior mesenteric artery lesions

Supplemental material, sj-pdf-2-jva-10.1177_11297298231225679 for A comparative study on the transbrachial and transfemoral approaches for the treatment of superior mesenteric artery lesions by Wenying Guo, Li Chen, Xiaoye Li, Longtu Zhu, Hao Zhang, Biao Wu, Qingsheng Lu, Shibo Xia, Zhichen Ding and Lei Zhang in The Journal of Vascular Access</p

sj-pdf-1-jva-10.1177_11297298231225679 – Supplemental material for A comparative study on the transbrachial and transfemoral approaches for the treatment of superior mesenteric artery lesions

Supplemental material, sj-pdf-1-jva-10.1177_11297298231225679 for A comparative study on the transbrachial and transfemoral approaches for the treatment of superior mesenteric artery lesions by Wenying Guo, Li Chen, Xiaoye Li, Longtu Zhu, Hao Zhang, Biao Wu, Qingsheng Lu, Shibo Xia, Zhichen Ding and Lei Zhang in The Journal of Vascular Access</p

Identifying Human Genome-Wide CNV, LOH and UPD by Targeted Sequencing of Selected Regions

<div><p>Copy-number variations (CNV), loss of heterozygosity (LOH), and uniparental disomy (UPD) are large genomic aberrations leading to many common inherited diseases, cancers, and other complex diseases. An integrated tool to identify these aberrations is essential in understanding diseases and in designing clinical interventions. Previous discovery methods based on whole-genome sequencing (WGS) require very high depth of coverage on the whole genome scale, and are cost-wise inefficient. Another approach, whole exome genome sequencing (WEGS), is limited to discovering variations within exons. Thus, we are lacking efficient methods to detect genomic aberrations on the whole genome scale using next-generation sequencing technology. Here we present a method to identify genome-wide CNV, LOH and UPD for the human genome via selectively sequencing a small portion of genome termed Selected Target Regions (SeTRs). In our experiments, the SeTRs are covered by 99.73%~99.95% with sufficient depth. Our developed bioinformatics pipeline calls genome-wide CNVs with high confidence, revealing 8 credible events of LOH and 3 UPD events larger than 5M from 15 individual samples. We demonstrate that genome-wide CNV, LOH and UPD can be detected using a cost-effective SeTRs sequencing approach, and that LOH and UPD can be identified using just a sample grouping technique, without using a matched sample or familial information.</p></div

Data production and mapping results for the three samples used.

<p>Data production and mapping results for the three samples used.</p